A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
A new in vitro rat liver platform capturing biological diversity for drug-induced liver injury assessment and reduction of animal use in drug discovery and development
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
PredictCan Presents Its DILI Platform at the 3RsC & IQ Consortium Liver MPS Webinar
PredictCan CTO Dr. Sara Cherradi presented the company’s individual-centric DILI platform during the “Revisiting Liver MPS” webinar organized as part of the 3Rs Collaborative and IQ Consortium Webinar Series.
New Study Introduces an Individual-Centric In Vitro–In Vivo Strategy for DILI Assessment
In collaboration with PRADO, PredictCan developed serum-derived educated rat liver spheroids that enable individualized in vitro and in vivo DILI assessment within the same animal, providing richer toxicity data while supporting a substantial reduction in animal use.
PredictCan Featured on BFM Business to Discuss the Future of Precision Medicine
PredictCan CEO and co-founder Dr. Hong Tuan Duong joined BFM Business to discuss how individual-centric preclinical models could help move precision medicine earlier into drug development and better account for patient diversity.
New Study Demonstrates PredictCan’s Individual-Centric Approach to DILI Prediction
Published in Frontiers in Toxicology in collaboration with Centre Antoine Lacassagne, the study demonstrates how PredictCan’s human serum-derived liver models combined with AI can capture chronic and individual-specific DILI while providing clinically relevant risk classification and mechanistic insights.
PredictCan and PreClinBio Solutions Launch Strategic India–Europe Collaboration
PredictCan Biotechnologies and PreClinBio Solutions LLP have established a strategic collaboration connecting complementary expertise in preclinical research and human-relevant biotechnology to support translational drug development and strengthen scientific ties between India and Europe.
PredictCan Joins FDA ISTAND Initiative to Advance Liver MPS for Drug Safety
PredictCan Biotechnologies is participating in a 3Rs Collaborative initiative accepted into the FDA ISTAND program, bringing together regulators, technology providers, and industry end-users to evaluate liver microphysiological systems for drug-induced liver injury assessment.
PredictCan Extends Its Cell Educating Technology™ to Pancreatic Cancer
A new study published in Translational Oncology, in collaboration with clinicians from Montpellier University Hospital, demonstrates the application of PredictCan’s patient-educated models to pancreatic cancer and their ability to reflect individual clinical treatment responses.